Webinar Series | Session 1

From PEG to rPEGs: A unique building block in next generation lipid nanoparticles
April 19, 4:00 p.m. CEST / 10:00 a.m. EDT
Outline
The COVID-19 pandemic marked the start of a medical revolution – that of mRNA technology. As the significance of RNA and nucleic acid technology becomes clear, so too does the role of lipids and lipid nanoparticles (LNPs), which ensure the safe delivery of the unstable RNA-based active ingredients into cells.

Researchers from the University of Mainz in Germany are studying ways to modify the polyethylene glycol (PEG) lipids that form part of LNPs to improve drug efficacy and immune response. In this webinar, technical experts will introduce these new PGME polymers, poly(glycidyl methyl ether), as a highly promising alternative to standard PEGs for use in RNA delivery. Furthermore, they will highlight current advances in leveraging these so-called rPEGs (randomized PEGs) in LNP-based delivery systems.
Key learnings for participants
  • Overview of PEGs and PEGylation
  • PEG alternatives: redesigning medical PEGs
  • Introduction to rPEGs and supporting data
  • LNP formulation opportunities with rPEGs

Talks in this session
  • From PEG to rPEGs: PEG isomer structures as a novel, non-immunogenic alternative for nanomedicine
  • rPEG as a unique building block in next generation lipid nanoparticles

Experts featured this session
  • Dr. Thomas Endres
    Head of New Products & Materials
    Evonik Health Care
  • Prof. Dr. Holger Frey
    Professor of Organic and Macromolecular Chemistry
    Johannes Gutenberg University Mainz

Fill out the form to register for your preferred webinar session:

More about other webinars in this series

Session 2 | May 10, 4:00 p.m. CEST / 10:00 a.m. EDT

Lipid manufacturing at Evonik: Facilities and capabilities

Lipids are one of the pillar excipients for drug delivery systems and are especially important for RNA-based therapies such as mRNA vaccines. As a CDMO partner offering end-to-end solutions, Evonik has built up a body of experience and expertise in every step of the manufacturing process such as route scouting, process development, optimization, purification, isolation, characterization, scale-up and commercialization. In this webinar, our experts will introduce Evonik’s new Lipid Launch Facility in Hanau, Germany, and talk through each of these important steps in detail outlining key capabilities for success. Solutions to common challenges are also addressed in this webinar.

Register

Session 3 | June 15, 4:00 p.m. CEST / 10:00 a.m. EDT

Purity is paramount: Customized approaches for superior quality control at Evonik

The quality of lipids in a lipid nanoparticle (LNP) assembly is critically important to the functionality of mRNA-based therapeutics. Any unwanted chemical reaction between the lipids and the labile mRNA will affect the product stability and efficacy of the vaccine or therapeutic. In this webinar, our expert describes Evonik’s approach to superior quality control lipid analytics. In two case studies, this webinar outlines the role of novel multivariate models in speeding up timelines and increasing knowledge, and demonstrates that Evonik lipids show a consistently negligible level of N-oxide and aldehyde impurities, enabling safe usage in LNPs.

Register

Headline H3 - Boxes and Form

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet.

Register